A virtual meeting spotlighting the stock ticker TLSI is scheduled for June 26, organized by Lake Street. This event aims to provide participants with insights into the company's performance and potential growth opportunities. It serves as a platform for investors to gain a deeper understanding of the market dynamics surrounding TLSI.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for TriSalus Life Sciences Inc (TLSI, Financial) is $11.31 with a high estimate of $16.00 and a low estimate of $9.00. The average target implies an upside of 112.44% from the current price of $5.33. More detailed estimate data can be found on the TriSalus Life Sciences Inc (TLSI) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, TriSalus Life Sciences Inc's (TLSI, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
TLSI Key Business Developments
Release Date: May 15, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- TriSalus Life Sciences Inc (TLSI, Financial) reported a 42% increase in net sales for Q1 2025 compared to Q1 2024, demonstrating strong revenue growth.
- The company achieved significant milestones, including the completion of phase one trials for Nelatolamo, positioning it for potential pharmaceutical partnerships.
- TLSI expanded its commercial footprint by increasing the number of unique ordering accounts by 39% compared to Q1 2024, adding 32 new accounts.
- The Centers for Medicare and Medicaid Services issued a new reimbursement code for TriNav, doubling its reimbursable use and supporting broader adoption.
- TLSI successfully raised approximately $22 million in gross proceeds through a private placement, strengthening its financial position for future investments.
Negative Points
- Despite revenue growth, TLSI reported operating losses of $7.3 million for Q1 2025, although this was an improvement from the previous year.
- The company's gross margin decreased slightly to 84% in Q1 2025 from 85% in Q1 2024 due to decreased factory volumes during clean room expansion.
- TLSI does not anticipate being EBITDA positive or cash flow positive in 2025, as it continues to invest in strategic areas of the business.
- The company faces challenges in scaling its sales force and ensuring new hires are effectively integrated to drive meaningful volume.
- There is uncertainty regarding the final data and outcomes from the Nelatolamo trials, which could impact potential partnerships and future revenue.
